Business Wire

Cirium: Radical Shifts in US Flight Schedules This Summer Reveal Why Airlines Need New Planning Tools to Stay Ahead of the Curve

Share

The new DiioTM Schedule Snapshotoffering released by Cirium, the aviation analytics firm, reveals how planning by the major US airlines changed over the summer, with 20% of flights being removed from their schedule for September.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005581/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The September flight schedules as published by American Airlines, Delta Air Lines, Southwest, and United Airlines initially in May compared with the revised plan published four months later. (Graphic: Business Wire)

At the start of May 2021, the plan for what carriers would fly in September was more or less in line with pre-pandemic levels in 2019. By the time they came to fly the September schedule, American Airlines, Delta Air Lines, Southwest and United Airlines had significantly cut back their flights.

Airlines are now making major changes to the way they schedule flights—publishing or removing them much closer to the date of departure as they struggle with the uncertainties brought on by the pandemic.

Prior to the pandemic schedules would remain fairly stable over a season, with few changes—positive or negative—as the plan was refined.

Only 3% of flights were removed from the September schedule in 2019 compared with the plan published in May that year.

The new Diio Schedule Snapshot web-based tool enables airlines and airports to track changes to the flights being scheduled at different points in time. It provides much more detail on schedule changes than has been done in the past.

“In today's environment where travel restrictions and vaccination programs are significantly impacting flight schedules, airlines have had to adapt and issue changes to their schedules frequently and much closer to the day of departure. The traditional methods used to analyze demand need to be more dynamic,” said Kevin O’Toole, Chief Strategy Officer at Cirium.

“Using Diio Schedules Snapshot, airlines and airports can understand schedule changes over time, optimize future schedules, build stronger models for planning and revenue management, and optimize yield through trend analysis.”

The analysis of the major US airlines evidences the radical shift in the summer flight schedule and the impact that the pandemic has had on the variance in airline planning year-over-year.

Understanding and comparing changes to the published flight schedule over time as it gets closer to actual departure, enables analysts to stay ahead of the curve, and provides new insights for planning and revenue management.

Reviewing historical data by publication date also provides insights on airline and airport strategies in an uncertain world.

Diio Schedule Snapshot is part of the unrivaled Cirium Diio suite of products for airline planning. The suite includes Diio Mi, SRS AnalyserTM, Cirium Scenario Planner, and Diio Traffic and Fares.

The new tool integrates with Cirium Diio Mior SRS Analyser and is the first of many more new tools in the Cirium pipeline to help airlines optimize their schedules and find new revenue opportunities.

More information on Diio Schedule Snapshot can be found at https://cirium.com/products/views/diio-schedule-snapshot

-End-

For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries please contact:

Mike Arnot, Juliett Alpha via cirium@juliettalpha.com

or the Cirium media team at media@cirium.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye